FDA Approved Gene Therapy for Sanfilippo Syndrome

Federal regulators recently authorized a new gene therapy designed to help infants born with this rare, degenerative condition.

Updated on Oct. 10, 2026 in Special Needs

Isometric editorial illustration of a clinical micropipette tool, representing medical gene therapy delivery.
The U.S. Food and Drug Administration granted approval in September for a new gene therapy treatment specifically for infants diagnosed with Sanfilippo syndrome. AI Illustration. Upload story photo >

In September 2026, the U.S. Food and Drug Administration approved a gene therapy treatment for Sanfilippo syndrome, a genetic disorder affecting 1 in 70,000 children. The therapy aims to prevent complications from the disease, which is caused by a gene change that disrupts enzyme production.

Why it matters

The approval provides a new medical intervention for infants, though the therapy is not authorized for older children because the disease is progressive and the treatment was not tested in that population. For families like the Merrills, whose child Mickey was diagnosed at age 3 and is ineligible, the shift underscores the limitations of current research for older patients.

The FDA authorized the therapy following research into a treatment that addresses the enzyme deficiency caused by the syndrome. The approval is specifically targeted at infants to prevent degenerative complications, as evidence is currently lacking for children who have already progressed in the disease.

The players

U.S. Food and Drug Administration

The federal agency responsible for overseeing the safety and efficacy of medical therapies and pharmaceuticals in the United States.

Declan Merrill

A child who received experimental gene therapy as an infant and now attends kindergarten.

Mickey Merrill

A child diagnosed with Sanfilippo syndrome at age 3 who requires daily medication and is ineligible for the new therapy.

The details

Sanfilippo syndrome is caused by a gene change that interferes with the body's ability to produce necessary enzymes. Doctors administer the gene therapy through injections to infants to potentially bypass these genetic roadblocks. Because the condition is progressive and causes damage over time, the therapy is not tested or approved for children who have already developed significant symptoms.

Timeline

  1. Five years ago, Declan Merrill received experimental gene therapy.

  2. September 2026 marked the FDA approval of the gene therapy.

  3. November 2, 2026 is the scheduled date for the Merrill family's Chefs Unite fundraiser.

Health Landscape

This development aligns with the FDA Orphan Drug Designation program, which facilitates the study and approval of treatments for rare genetic conditions. It represents a shift in pediatric care toward gene-based interventions, though it highlights the distinct challenges in treating progressive diseases.

For families navigating a Sanfilippo syndrome diagnosis, this development highlights the critical importance of early screening and potential intervention windows. Parents should discuss emerging clinical trial eligibility and diagnostic timelines with their specialist or pediatrician.

The takeaway

The recent FDA approval marks a major step in targeting the underlying causes of Sanfilippo syndrome early in infancy. If you are concerned about developmental delays or rare genetic conditions, consult your physician about current screening options and clinical research enrollment.

What happens next

The Merrill family is hosting a Chefs Unite fundraiser in Newark on November 2, 2026, to support ongoing research efforts.

Further reading

Learn more about the latest innovations in Special Needs support and care.

Source note: This article includes information reported by Spotlight Delaware.